Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease

Movement Disorders

Volumn 18, Issue 3, 2003, Pages 287-293

  Adler, Charles H ^a   Caviness, John N ^a   Hentz, Joseph G ^a   Lind, Marlene ^a   Tiede, Judy ^a  

^a MAYO CLINIC   (United States)

Author keywords

Excessive daytime sleepiness; Modafinil; Parkinson's disease

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; ENTACAPONE; MODAFINIL; NEUROLEPTIC AGENT; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; TOLCAPONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; ERYTHEMA; FEMALE; HEART ATRIUM FIBRILLATION; HOT FLUSH; HUMAN; HYPERTENSION; INFLUENZA; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PNEUMATOSIS INTESTINALIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; RECTUM PROLAPSE; SAMPLE SIZE; SCORING SYSTEM; SKIN BRUISING; SLEEP TIME; SOMNOLENCE; TONGUE DISEASE;

ADULT; AGED; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DISORDERS OF EXCESSIVE SOMNOLENCE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WAKEFULNESS;

EID: 0037355884     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10390     Document Type: Article

References (31)

1. Comella CL. Sleep and Parkinson's disease. In: Adler CH, Ahlskog JE, editors. Parkinson's disease and movement disorders: diagnosis and treatment guidelines for the practicing physician. Totowa: Humana Press; 2000. p 151-160.
2. Hobson DE, Lang AE, Martin WRW, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002;287:455-463.
3. van Hilten JJ, Weggeman M, van der Velde EA, Kerkhof GA, van Dijk JG, Roos RAC. Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease. J Neural Transm 1993;5:235-244.
4. Rye DB, Bliwise DL, Dihenia B, Gurecki P. Daytime sleepiness in Parkinson's disease. J Sleep Res 2000;9:63-69.
5. Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson's disease: A community-based study. Mov Disord 1999;14:922-927.
6. Broughton RJ, Fleming JAE, George CFP, Hill JD, Kryger MH, Moldofsky H, Montplaisir JY, Morehouse RL, Moscovitch A, Murphy WF. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997;49:444-451.
7. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000;54:1166-1175.
8. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43:88-97.
9. Pigeau R, Naitoh P, Buguet A, McCann C, Baranski J, Taylor M, Thompson M, Mack I. Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature. J Sleep Res 1995;4:212-228.
10. Fuxe K, Janson AM, Rosen L, Finnman UB, Tanganelli S, Morari M, Goldstein M, Agnati LF. Evidence for a protective action of the vigilance promoting drug Modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis. Exp Brain Res 1992;88:117-130.
11. Ueki A, Rosen L, Andbjer B, Finnman UB, Altamimi U, Janson AM, Goldstein M, Agnati LF, Fuxe K. The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactivity and of dopamine stores in nigrostriatal dopamine neurons in the male rat after a partial transection of the dopamine pathway. Exp Brain Res 1993;93:259-270.
12. Grozinger M, Hartter S, Hiemke C, Griese EU, Roschke J. Interaction of modafanil and clomipramine as comedication in a narcoleptic patient. Clin Neuropharmacol 1998;21:127-129.
13. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540-545.
14. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
15. Krupp LB, Larocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-1123.
16. Friedman J, Friedman H. Fatigue in Parkinson's disease. Neurology 1993;43:2016-2018.
17. Schwartz J, Jandorf L, Krupp L. The measurement of fatigue: a new instrument. J Psychosom Res 1993;37:753-762.
18. Fahn S, Elton RL, Committee. amotUD. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne CD, eds. Recent developments in Parkinson's disease. Vol. II. Florham Park, NJ: Macmillan; 1987. p 153-163.
19. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
20. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The "ON-OFF" phenomenon in Parkinson's disease: relation to levodopa absorption and transport. N Engl J Med 1984;310:483-488.
21. Hauser RA, Gauger L, Anderson WM, Zesiewicz TA. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord 2000;15:658-663.
22. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999;52:1908-1910.
23. Frucht SJ, Greene PE, Fahn S. Sleep episodes in Parkinson's disease: a wake-up call. Mov Disord 2000;15:601-603.
24. Sanjiv CC, Schulzer M, Mak E, Fleming J, Martin WRW, Brown T, Calne SM, Tsui J, Stoessl AJ, Lee CS, Calne DB. Daytime somnolence in patients with Parkinson's disease. Parkinsonism Relat Disord 2001;7:283-286.
25. Hauser RA, Wahba MN, Anderson WM, Aesiewicz TA. Modafinil treatment of pramipexole-associated somnolence. Mov Disord 2000;15:1269-1271.
26. Mitler MM, Miller JC. Methods of testing for sleeplessness. Behav Med 1996;21:171-183.
27. Benbadis SR, Mascha E, Perry MC, Wolgamuth BR, Smolley LA, Dinner DS. Association between the Epworth Sleepiness Scale and the Multiple Sleep Latency Test in a clinical population. Ann Intern Med 1999;130:289-292.
28. Chervin RD, Aldrich MS. The Epworth Sleepiness Scale may not reflect objective measures of sleepiness or sleep apnea. Neurology 1999;52:125-131.
29. Ulivelli M, Rossi S, Lombardi C, Bartalini S, Rocchi R, Giannini F, Passero S, Battistini N, Lugaresi E. Polysomnographic characterization of pergolide-induced sleep attacks in idiopathic PD. Neurology 2002;58:462-465.
30. Tracik F, Ebersbach G. Sudden daytime sleep onset in Parkinson's disease: polysomnographic recordings. Mov Disord 2001;16:500-506.
31. Melamed E. Neurobehavioral abnormalities in Parkinson's disease. In: Watts RL, Koller WC, editors. Movement disorders: neurological principles and practice. New York: McGraw-Hill; 1997. p 257-262.